Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores—— A retrospective, propensity score matching analysis

BACKGROUND: The use of neoadjuvant chemotherapy (NAC) in resectable colorectal liver metastases (CRLM) patients is controversial. High-risk patients are more likely to benefit from NAC despite its hepatotoxic effects. Since patients with a high tumor burden receive NAC more frequently, previous retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Feng-Lin, Wang, Yan-Yan, Liu, Wei, Xing, Bao-Cai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483158/
https://www.ncbi.nlm.nih.gov/pubmed/36132151
http://dx.doi.org/10.3389/fonc.2022.973418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483158/
https://www.ncbi.nlm.nih.gov/pubmed/36132151
http://dx.doi.org/10.3389/fonc.2022.973418

Ejemplares similares